Marinus Pharmaceuticals, Inc. announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. Mr. Johnson will serve as a Class I member of the Board. The term of the Class I directors will expire at the 2024 Annual Meeting of Stockholders.

Additionally, the Board appointed Mr. Johnson to serve on the Compensation Committee of the Board, replacing Saraswathy V. Nochur, Ph.D. During his tenure at Merck & Co., Mr. Johnson held numerous senior leadership roles, primarily within commercial operations, sales, and marketing, across a wide range of therapeutic categories. He led large scale regional, national, and global sales and marketing organizations worth over $3 billion in annual revenue, including in his role as Vice President of the U.S. Human Health East Commercial Operations Group for the Primary Care Sales division and prior to that, Global Brand Leader for Merck's Migraine franchise where he successfully led product launches in various countries around the world. Most recently, Mr. Johnson was the Chief Learning Officer for Merck's Global Learning and Development department.

Mr. Johnson is a member of the Board of Directors for Trevena, Inc., Vice Chair on the Board of Trustees for Tabor Children's Services, Inc. and serves as a member of the strategic advisory board for GP Strategies Corporation.